Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has repurchased 9,631,818 ordinary shares for a total cost of £130,317,376.42 as part of its $250 million share repurchase program. These repurchases occurred between June 15 and June 19, 2026, with the company intending to cancel the acquired shares. Following these transactions and the cancellation, Hikma will have 212,254,635 ordinary shares in issue, excluding treasury shares, resulting in a total of 212,254,635 voting rights. The company currently holds 12,833,233 ordinary shares in treasury.

Disclaimer*

UK 100

Latest directors dealings